Causeway Hospital, Northern Trust, NI, UK.
Curr Drug Deliv. 2012 Jul;9(4):333-7. doi: 10.2174/156720112801323143.
Inflammatory bowel diseases (IBD) are chronic relapsing and remitting disorders that have varying degrees of severity. However multiple studies have confirmed that a large proportion of patients on maintenance treatment lose response to anti-TNF therapy. This has led to increasing interest in the concept of 'switching therapy out-of-class' i.e. a nonanti- TNF antibody when patients either fail to respond (primary non-response, develop secondary non-response) or do not tolerate anti-TNF therapies. The most widely known and studied alternative class of antibodies therapies at present are the selective adhesion molecule inhibitors. Several antibodies exist which constitute selection adhesion molecule inhibitors, including Natalizumab, MLN-0002 (Vedolizumab) and ISIS 2302 (Alicaforsen) will be discussed in this review.
炎症性肠病（IBD）是一种慢性复发和缓解的疾病，其严重程度各有不同。然而，多项研究证实，很大一部分接受维持治疗的患者对 TNF 拮抗剂治疗失去应答。这导致人们越来越关注“转换治疗”的概念，即在患者对 TNF 拮抗剂治疗无应答（原发性无应答、发生继发性无应答）或不能耐受时，使用非 TNF 拮抗剂的抗体。目前，在已知和研究的抗体治疗中，最广泛的替代类别是选择性黏附分子抑制剂。目前存在几种抗体，它们构成了选择黏附分子抑制剂，包括那他珠单抗、MLN-0002（vedolizumab）和 ISIS 2302（alicaforsen），将在本综述中讨论。
